Cara Therapeuticsreports that it has dosed the first patient in its Phase 1 pharmacokinetic and safety trial of Oral CR845 tablets in patients with stage III-V chronic kidney disease (CKD) who are not on dialysis.

“We believe Oral CR845 has the potential to substantially broaden our market potential in patients with CKD-aP,” said Derek Chalmers, Ph.D., D.Sc., president and CEO of Cara.